The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. or Refresh this page to see your newly added stocks. featured in The Global Fintech Index 2020 as the top Fintech company of the country. Sign in with Google © American Consumer News, LLC dba MarketBeat® 2010-2020. There are currently 2 buy ratings for the stock… Please read the full disclaimer here.
Find the latest Heat Biologics, Inc. (HTBX) stock quote, history, news and other vital information to help you with your stock trading and investing.
All rights reserved. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments.
Do Not Sell My Information. Receive a free world-class investing education from MarketBeat. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. © American Consumer News, LLC dba MarketBeat® 2010-2020. Fundamental company data provided by Morningstar and Zacks Investment Research. © 2020 Cable News Network. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The price has fallen in 6 of the last 10 days and is down by -11.34% for this period. Heat Biologics finds support from accumulated volume at $1.04 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. The 1-10 reverse split was announced on Friday, January 19th 2018. All users should speak with their financial advisor before buying or selling any securities. Heat Biologics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Learn more. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". Volume fell during the last trading day despite gaining prices. The price target was set to $4.00 - $4.00. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Get daily stock ideas top-performing Wall Street analysts. Disclaimer. Heat Biologics, Inc. (NASDAQ:HTBX…
View insider buying and selling activity for Heat Biologics. The stock should be watched closely. The 3-month trading volume is 10.98 Million shares. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Heat Biologics does not have a long track record of dividend growth.
Heat Biologics has received a consensus rating of Buy. Please log in to your account or sign up in order to add this asset to your watchlist. WARNING: Trend forecast is still in the development phase and should be used with caution. View analysts' price targets for Heat Biologics. Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257
Get short term trading ideas from the MarketBeat Idea Engine. Chart for HTBX.
MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Sign in with intratio Looking for new stock ideas?
Most stock quote data provided by BATS.
Terms of Use and Privacy Policy. Sign in with Microsoft, Sign in with your credentials Since then, HTBX stock has increased by 50.7% and is now trading at $1.0550.
A Triangle drugmaker that shifted its focus to creating a vaccine for Covid-19 says it continues to believe in its candidate, ... Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. View institutional ownership trends for Heat Biologics.
The HTBX stock price is -313.46% off its 52-week high price of $4.3 and 80.77% above the 52-week low of $0.2. Only 7.06% of the stock of Heat Biologics is held by institutions.
QQQ 294.61 (+0.07%) AAPL 118.69 (-0.11%) This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts.
In the past three months, Heat Biologics insiders have not sold or bought any company stock. View our earnings forecast for Heat Biologics. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days.
4 Biotech Stocks To Watch, Heat Biologics EPS misses by $0.03, beats on revenue, Durham drugmaker's Covid vaccine runs risk of being overshadowed by big pharma. Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion.
The chart below shows how a company's share price and consensus price target have changed over time. Interactive Chart | Fundamental Charts. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Heat Biologics, Inc. (NASDAQ:HTBX) released its quarterly earnings data on Friday, November, 13th. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. Heat Biologics Inc. HTBX 1.14 0.03 (2.56%).
Revenue of $0.8M beats by $0.47M. Heat Biologics, Inc. () Stock Market info Recommendations: Buy or sell Heat Biologics stock? Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Heat Biologics has received 59.42% “outperform” votes from our community. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Learn more. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Get short term trading ideas from the MarketBeat Idea Engine. HTBX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., California Public Employees Retirement System, State Street Corp, and Strategic Wealth Management Group LLC. Volume fell on the last day by -3 million shares and in total, 5 million shares were bought and sold for approximately $4.90 million. Heat Biologics has a market capitalization of $156.73 million and generates $3.05 million in revenue each year. Please log in to your account or sign up in order to add this asset to your watchlist.
Top institutional shareholders include BlackRock Inc. (1.62%), California Public Employees Retirement System (0.20%), State Street Corp (0.08%), Strategic Wealth Management Group LLC (0.03%) and Magnus Financial Group LLC (0.02%).
Sign in with Google Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Bionano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).
The high price target for HTBX is $4.00 and the low price target for HTBX is $2.00. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
HTBX stock was sold by a variety of institutional investors in the last quarter, including Magnus Financial Group LLC. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! Your losses are our losses too. Given the current short-term trend, the stock is expected to fall -20.29% during the next 3 months and, with a 90% probability hold a price between $0.63 and $0.98 at the end of this 3-month period. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. View which stocks are hot on social media with MarketBeat's trending stocks report.
Our recommended stop-loss: We hold a sell evaluation for this stock. Your losses are our losses too. During the day the stock fluctuated 7.68% from a day low at $1.00 to a day high of $1.08.
The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.